No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer

FRIDAY, July 16, 2021 -- For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news